Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 8Lymphoid 5Thoracic 4Head & Neck 2Gastrointestinal 2Sarcoma 1CNS 1

Conditions

Thyroid Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × ponatinib × Head & Neck × Clear all
NCT01838642 2017-02-15

Ponatinib for Advanced Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 13 charts
Head & Neck

Thyroid Neoplasms

NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Dana-Farber Cancer Institute

Phase 2/3 Terminated
3 enrolled 9 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡